API | pegvaliase

pegvaliase (Palynziq) Report issue

Biologics Recombinant protein Orphan Drug ^FDA Approved ^FDA First in Class Fast Track ^FDA

AACT DrugBank Drugs@FDA PubChem

Active Ingredient History

NOW

Pegvaliase, sold under the brand name Palynziq, is a medication used for the treatment of the genetic disease phenylketonuria. It is a phenylalanine (Phe)‑metabolizing enzyme. Chemically, it is a pegylated derivative of the enzyme phenylalanine ammonia-lyase that metabolizes phenylalanine to reduce its blood levels. ^Wikipedia

Chemistry

SMILES: Missing data
InChIKey: Missing data
Mol. Mass: Missing data
ALogP: Missing data
ChEMBL Molecule:
pegvaliase

More Chemistry

Pharmacology

Mechanisms of Action:
Multi-specific: No
Black Box: Yes
Availability: Missing data
Delivery Methods: Parenteral
Pro Drug: No

Drug Pricing (per unit)

United States

$181.0400 - $487.2300

More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

bmn165 | bmn 165 | pegvaliase | pegvaliase-pqpz

Organizations (1)

Research & Development (1)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Marketing (1)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Indications (1)

Approved Indications (1)

Phenylketonurias (approved 2018)

Experimental Indications - Clinical Trial Phases 1-4 (1)

Phenylketonurias (Phase 3)

Overview

Highest Phase: Phase 3
# of Trials: 4
# of Trial Organizations: 1

Trials by Phase

Trial	Phase	Start Date	Organizations	Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue